Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation: A Case Report

T. Motomura, T. Yoshizumi, M. Ohira, Y. Mano, T. Toshima, S. Itoh, N. Harada, N. Harimoto, T. Ikegami, Y. Soejima, Y. Maehara

Research output: Contribution to journalArticle

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.

Original languageEnglish
Pages (from-to)2409-2410
Number of pages2
JournalTransplantation Proceedings
Volume49
Issue number10
DOIs
Publication statusPublished - Dec 2017

Fingerprint

Thrombotic Microangiopathies
Thrombomodulin
Liver Transplantation
Transplants
Therapeutics
Hemolytic Anemia
Hepatitis C
Consciousness
Liver Cirrhosis
Thrombocytopenia
Transplantation
Erythrocytes
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation : A Case Report. / Motomura, T.; Yoshizumi, T.; Ohira, M.; Mano, Y.; Toshima, T.; Itoh, S.; Harada, N.; Harimoto, N.; Ikegami, T.; Soejima, Y.; Maehara, Y.

In: Transplantation Proceedings, Vol. 49, No. 10, 12.2017, p. 2409-2410.

Research output: Contribution to journalArticle

Motomura, T. ; Yoshizumi, T. ; Ohira, M. ; Mano, Y. ; Toshima, T. ; Itoh, S. ; Harada, N. ; Harimoto, N. ; Ikegami, T. ; Soejima, Y. ; Maehara, Y. / Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation : A Case Report. In: Transplantation Proceedings. 2017 ; Vol. 49, No. 10. pp. 2409-2410.
@article{140c4fbb42024790965a2015531012b2,
title = "Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation: A Case Report",
abstract = "Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.",
author = "T. Motomura and T. Yoshizumi and M. Ohira and Y. Mano and T. Toshima and S. Itoh and N. Harada and N. Harimoto and T. Ikegami and Y. Soejima and Y. Maehara",
year = "2017",
month = "12",
doi = "10.1016/j.transproceed.2017.09.014",
language = "English",
volume = "49",
pages = "2409--2410",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation

T2 - A Case Report

AU - Motomura, T.

AU - Yoshizumi, T.

AU - Ohira, M.

AU - Mano, Y.

AU - Toshima, T.

AU - Itoh, S.

AU - Harada, N.

AU - Harimoto, N.

AU - Ikegami, T.

AU - Soejima, Y.

AU - Maehara, Y.

PY - 2017/12

Y1 - 2017/12

N2 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.

AB - Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85040767428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040767428&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2017.09.014

DO - 10.1016/j.transproceed.2017.09.014

M3 - Article

C2 - 29198692

AN - SCOPUS:85040767428

VL - 49

SP - 2409

EP - 2410

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -